Adam Dubow - Nov 15, 2023 Form 4 Insider Report for Day One Biopharmaceuticals, Inc. (DAWN)

Role
General Counsel
Signature
/s/ Charles N. York II, as Attorney-in-Fact
Stock symbol
DAWN
Transactions as of
Nov 15, 2023
Transactions value $
-$62,109
Form type
4
Date filed
11/17/2023, 06:30 PM
Previous filing
Nov 16, 2023
Next filing
Jan 9, 2024

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction DAWN Common Stock Options Exercise +11.9K +377.27% 15K Nov 15, 2023 Direct F1
transaction DAWN Common Stock Options Exercise +1.75K +11.67% 16.7K Nov 15, 2023 Direct F1
transaction DAWN Common Stock Sale -$62.1K -5.31K -31.74% $11.69 11.4K Nov 16, 2023 Direct F2

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction DAWN Restricted Stock Units Options Exercise $0 -11.9K -25% $0.00 35.6K Nov 15, 2023 Common Stock 11.9K Direct F1, F3
transaction DAWN Restricted Stock Units Options Exercise $0 -1.75K -7.69% $0.00 21K Nov 15, 2023 Common Stock 1.75K Direct F1, F4
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Each Restricted Stock Unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock upon settlement for no consideration.
F2 The sale of shares is for the sole purpose of covering the Reporting Person's tax liability with respect to the settlement of RSUs.
F3 The RSUs vest as to 25% of the total award on November 15, 2023, and 1/12th of the remaining amount vest in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.
F4 The RSUs will vest as to 1/16th of the total award in quarterly installments on February 15, May 15, August 15 and November 15, subject to the Reporting Person's provision of service to the Issuer on each vesting date.